Most Viewed: Last ONE YEAR
  • Topic: Circulating Tumor Cells: Diagnostics and Clinical Applications|Open Access

    Insights into mechanisms of tumor dissemination from circulating tumor cell lines of small cell lung cancer

    Gerhard Hamilton , Barbara Rath
    Despite the fact that the majority of cancer patients succumb to metastatic disease, most aspects of tumor metastasis are not understood in detail at present. Cell biologic steps of dissemination are difficult to characterize in human tumors and research is in large part confined to cell line and experimental animal studies. Epithelial-mesenchymal transition (EMT), intravasation of malignant cells, dissemination as circulating tumor cells (CTCs) and eventually mesenchymal-epithelial transition (MET) at distal sites are steps believed to be involved in metastasis. Small cell lung cancer... Read more
    J Cancer Metastasis Treat 2016;2:446-52. | doi:10.20517/2394-4722.2016.57
    Published on: 16 Dec 2016  | Viewed:5779  | Downloaded:156
    +HTML| PDF
  • Review|Open Access

    Targeting Toll-like receptors against cancer

    Bing Du , Qiu-Li Jiang , Joseph Cleveland , Bing-Rong Liu , Dekai Zhang
    The discovery of Toll-like receptors (TLRs) about 20 years ago was a remarkable achievement not only in the field of immunology but also in the field of medicine. The TLRs are a family of pattern recognition receptors which play an important role in immune responses by recognizing pathogen-associated molecular patterns. The TLRs also recognize danger-associated molecular patterns, which are associated with some diseases such as cancer. Recent evidence shows that TLRs are expressed not only in immune cells but also in tumor cells. The TLRs appear to play a role in tumor progression and... Read more
    J Cancer Metastasis Treat 2016;2:463-70. | doi:10.20517/2394-4722.2016.62
    Published on: 29 Dec 2016  | Viewed:4483  | Downloaded:360
    +HTML| PDF
  • Review|Open Access

    DNA damage-induced nuclear factor-kappa B activation and its roles in cancer progression

    Wei Wang , Arul M. Mani , Zhao-Hui Wu
    DNA damage is a vital challenge to cell homeostasis. Cellular responses to DNA damage (DDR) play essential roles in maintaining genomic stability and survival, whose failure could lead to detrimental consequences such as cancer development and aging. Nuclear factor-kappa B (NF-kB) is a family of transcription factors that plays critical roles in cellular stress response. Along with p53, NF-kB modulates transactivation of a large number of genes which participate in various cellular processes involved in DDR. Here the authors summarize the recent progress in understanding DNA damage response... Read more
    J Cancer Metastasis Treat 2017;3:45-59. | doi:10.20517/2394-4722.2017.03
    Published on: 27 Mar 2017  | Viewed:2366  | Downloaded:142
    +HTML| PDF
  • Topic: Circulating Tumor Cells: Diagnostics and Clinical Applications|Open Access

    A versatile method for enumeration and characterization of circulating tumor cells from patients with breast cancer

    Ujjwala M. Warawdekar , Vani Parmar , Aruna Prabhu , Abhay Kulkarni , Meenal Chaudhari , Rajendra A. Badwe
    Aim: To establish a standardized protocol for the isolation and enumeration of circulating tumor cells (CTCs) from peripheral blood of patients with metastatic breast cancer. Methods: The protocol used tumor cells spiked in a lymphoid cell line with detection by flow cytometry and quantitative reverse transcription polymerase chain reaction (QRT-PCR). Cells of the human mammary cancer subtypes were spiked into Jurkat cells, which served as the lymphocyte designate in numbers from 10 to 500 per 105 Jurkat cells. This mixed population was probed for CD45, EpCAM, and pancytokeratin acquired... Read more
    J Cancer Metastasis Treat 2017;3:23-33. | doi:10.20517/2394-4722.2016.66
    Published on: 23 Feb 2017  | Viewed:2066  | Downloaded:124
    +HTML| PDF
  • Commentary|Open Access

    A new twist to neurotransmitter receptors and cancer

    Hildegard M. Schuller
    J Cancer Metastasis Treat 2017;3:71-7. | doi:10.20517/2394-4722.2017.18
    Published on: 28 Apr 2017  | Viewed:1643  | Downloaded:106
    +HTML| PDF
  • Review|Open Access

    Role of adenosine in tumor progression: focus on A2B receptor as potential therapeutic target

    Claudia Sorrentino , Silvana Morello
    Adenosine receptors are a family of G-coupled receptors which mediate the anti-inflammatory and immune-suppressive effects of adenosine in a damaged tissue. A large number of evidence indicate that the accumulation of adenosine under hypoxic conditions favors tumor progression, helping cancer cells to evade immune responses. Tumor cells and/or lymphoid and myeloid cells can express the adenosine-generating enzyme CD73 and/or A2A receptor, which in turn strongly suppresses an effective T-cell-mediated response, while promotes the activity of suppressive cells such as Treg and myeloid-derived... Read more
    J Cancer Metastasis Treat 2017;3:127-38. | doi:10.20517/2394-4722.2017.29
    Published on: 17 Jul 2017  | Viewed:1609  | Downloaded:187
    +HTML| PDF
  • Original Article|Open Access

    Real-time quantitative PCR array to study drug-induced changes of gene expression in tumor cell lines

    Stefano Amatori , Giuseppe Persico , Mirco Fanelli
    Aim: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is still the “gold standard” for quantitative analysis of mRNA and the study of differentially expressed genes. Methods: The authors describe a RT-qPCR array that exploits SYBR Green dye-based detection to perform reliable gene expression analysis on 41 genes involved in several pathways linked to DNA damage response, cell cycle progression, cellular senescence, and programmed cell death. To validate the RT-qPCR array, the authors investigated changes of the gene expression profile of HeLa cells treated with two... Read more
    J Cancer Metastasis Treat 2017;3:90-9. | doi:10.20517/2394-4722.2017.22
    Published on: 24 May 2017  | Viewed:1527  | Downloaded:119
    +HTML| PDF
  • Topic: Circulating Tumor Cells: Diagnostics and Clinical Applications|Open Access

    Profiling of circulating tumor cells in liquid biopsies from metastatic cancer patients

    Pravin D. Potdar , Keerti Sen
    Aim: Circulating tumor cells (CTCs) are crucial to tumor metastasis and valuable for prediction of clinical outcome in patients with solid tumors. Here, the authors aimed to establish a method for enumeration and characterization of CTCs from liquid biopsies. Methods: Peripheral blood mononuclear cells (PBMCs) were separated from blood samples from patients with metastatic cancer using Ficoll-Hypaque gradients and cultured to isolate and enumerate CTCs. Cultured CTCs were morphologically characterized by light and phase contrast microscopy. The tumorigenicity of Ficoll-Hypaque-separated... Read more
    J Cancer Metastasis Treat 2017;3:6-15. | doi:10.20517/2394-4722.2016.53
    Published on: 23 Jan 2017  | Viewed:1468  | Downloaded:139
    +HTML| PDF
  • Review|Open Access

    Cytogenetic and molecular basis of BCR-ABL myelodysplastic syndrome: diagnosis and prognostic approach

    Mostafa Paridar , Omid Kiani Ghalesardi , Mohammad Seghatoleslami , Ahmad Ahmadzadeh , Abbas Khosravi , Najmaldin Saki
    Myelodysplastic syndromes (MDS) include a heterogeneous group of blood disorders generally afflicting older people. Several genetic factors have been reported from these patients that have an important role in the diagnosis, prognosis, and treatment of this disease. BCR-ABL1 is a genetic factor that has occasionally been reported in some studies. This review attempts to characterize MDS patients reported to harbor this fusion and to assess the diagnostic, therapeutic, and prognostic potential of BCR-ABL1 fusionin MDS patients. This review showed that BCR-ABL fusion has been reported in 22... Read more
    J Cancer Metastasis Treat 2017;3:38-44. | doi:10.20517/2394-4722.2016.61
    Published on: 28 Feb 2017  | Viewed:1280  | Downloaded:143
    +HTML| PDF
  • Original Article|Open Access

    TGF-β stimulation of EMT programs elicits non-genomic ER-α activity and anti-estrogen resistance in breast cancer cells

    Maozhen Tian , William P. Schiemann
    Aim: Estrogen receptor-α (ER-α) activation drives the progression of luminal breast cancers. Signaling by transforming growth factor-β (TGF-β) typically opposes the actions of ER-α; it also induces epithelial-mesenchymal transition (EMT) programs that promote breast cancer dissemination, stemness and chemoresistance. The impact of EMT programs on nongenomic ER-α signaling remains unknown and was studied herein. Methods: MCF-7 and BT474 cells were stimulated with TGF-β to induce EMT programs, at which point ER-α expression, localization, and nongenomic interactions with receptor tyrosine... Read more
    J Cancer Metastasis Treat 2017;3:150-60. | doi:10.20517/2394-4722.2017.38
    Published on: 21 Aug 2017  | Viewed:1154  | Downloaded:90
    +HTML| PDF
  • Original Article|Open Access

    Combination of insulin-like growth factor-1, IGF binding protein-3, chromogranin A and prostate specific antigen can improve the detection of prostate cancer

    Saleh Ahmed Kamaleldin Saleh , Heba Mohamed Adly , Anmar Mohammed Nassir
    Aim: Prostate cancer (PCa) is the second most prevalent male cancer worldwide and designated the sixth most frequent male cancer in Arab countries. Although prostate specific antigen (PSA) has become the best and most valuable biomarker for screening of PCa, elevated levels of PSA can reflect the presence of malignant cells but can overlap with benign prostatic diseases. There is a necessity to develop and improve current tools for early detection and diagnosis of PCa. This study was done to evaluate the validation of serum insulin-like growth factor-1 (IGF-1), IGF binding protein-3... Read more
    J Cancer Metastasis Treat 2017;3:82-9. | doi:10.20517/2394-4722.2017.20
    Published on: 24 May 2017  | Viewed:1114  | Downloaded:59
    +HTML| PDF
  • Topic: Circulating Tumor Cells: Diagnostics and Clinical Applications|Open Access

    Circulating tumor cells: hope to diagnose and treat metastatic cancer

    Pravin D. Potdar
    J Cancer Metastasis Treat 2017;3:1-5. | doi:10.20517/2394-4722.2016.72
    Published on: 12 Jan 2017  | Viewed:1101  | Downloaded:107
    +HTML| PDF
  • Topic: Circulating Tumor Cells: Diagnostics and Clinical Applications|Open Access

    Lung cancer biopsy dislodges tumor cells into circulating blood

    Noriyoshi Sawabata , Tomotaka Kitamura , Yuko Nitta , Tomoyo Taketa , Takeshi Ohno , Tatsuya Fukumori , Takeru Hyakutake , Takahito Nakamura
    Aim: A “seed” of lung cancer metastasis is circulating tumor cells (CTCs), which may be dislodged from a tumor during biopsy. This possibility was assessed among patients who underwent lung tumor biopsy using flexible fiber-topic bronchoscopy (FFB). Methods: The study involved six patients with non-small cell lung cancer who underwent FFB biopsy to diagnose a lesion pathologically (5 males and 1 female, median age 63 years, six adenocarcinomas, of four clinical-stage IA, one stage IB, and one stage IIIA), CTCs were extracted from the peripheral vein blood at pre-FFB and at post-FFB using a... Read more
    J Cancer Metastasis Treat 2017;3:16-20. | doi:10.20517/2394-4722.2016.67
    Published on: 23 Jan 2017  | Viewed:1052  | Downloaded:117
    +HTML| PDF
  • Original Article|Open Access

    Impact of health care insurance on overall survival of patients with multiple myeloma and monoclonal gammopathy of undetermined significance

    Srinivas S. Devarakonda , Runhua Shi , Ellen Friday , Reinhold Munker , Jonathan Glass , Francesco Turturro
    Aim: Health care insurance improves access to care and thus outcome in patients with solid tumors. Little information on the impact of health care insurance on hematological malignancies including multiple myeloma exists. The authors aimed to analyze the effect of health care insurance on the survival of patients with multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) at Louisiana State University Health Sciences Center in Shreveport, LA. Methods: Two hundred fifty seven patients were reviewed, of which 208 had MM and 49 had MGUS. Results: One hundred and... Read more
    J Cancer Metastasis Treat 2017;3:100-4. | doi:10.20517/2394-4722.2017.19
    Published on: 9 Jun 2017  | Viewed:1033  | Downloaded:63
    +HTML| PDF
  • Original Article|Open Access

    Papaya black seeds have beneficial anticancer effects on PC-3 prostate cancer cells

    Khalid S. Alotaibi , Haiwen Li , Reza Rafi , Rafat A. Siddiqui
    Aim: The study investigated the effect of papaya seeds on prostate cancer (PC) using PC-3 cell line because papaya seeds have effects on the male reproductive system notably decreasing sperm concentration, motility, and viability, leading to azoospermia after short-to-long-term treatment. Methods: The black seeds from yellow (ripe) papaya and white seeds from green (unripe) papaya were harvested and then extracted in water, 80% methanol, and hexane. The cytotoxic effects of seeds extracts were determined using a WST-1 proliferation assay. The amount of total polyphenols was determined using... Read more
    J Cancer Metastasis Treat 2017;3:161-8. | doi:10.20517/2394-4722.2017.33
    Published on: 28 Aug 2017  | Viewed:1022  | Downloaded:78
    +HTML| PDF
  • Original Article|Open Access

    ERCC1 expression in patients with colorectal cancer: a pilot study

    Kinjal K. Gajjar , Deep Kumari Yadav , Toral P. Kobawala , Trupti I. Trivedi , Hemangini H. Vora , Nandita R. Ghosh
    Aim: Excision repair cross complementation group 1 (ERCC1) has a key role in enhanced DNA damage repair caused by oxaliplatin-based therapy and may lead to resistance of these platinum drugs in colorectal cancer (CRC) patients. Hence, the present preliminary study aimed to explore the role of ERCC1 C/T polymorphism at codon 118 as well as its immunoreactivity in patients with primary CRC. Methods: ERCC1 polymorphism was studied using PCR-RFLP and ERCC1 protein expression was examined by immunohistochemistry in 50 CRC patients. Results: ERCC1 codon 118 C/T polymorphism analysis reported the... Read more
    J Cancer Metastasis Treat 2016;2:471-6. | doi:10.20517/2394-4722.2016.52
    Published on: 29 Dec 2016  | Viewed:979  | Downloaded:122
    +HTML| PDF
  • Topic: Cancer Immunotherapy|Open Access

    Systemic humoral responses of non-muscle-invasive bladder cancer during BCG treatment: less is more

    Fernando M. Calais da Silva , Paula A. Videira , Dário Ligeiro , Maria Guadalupe Cabral , Richard Sylvester , Fernando E. Calais da Silva , Hélder Trindade
    Aim: Intravesical Bacille Calmette-Guérin (BCG) is the mainstay adjuvant treatment of non-muscle-invasive bladder cancer. However, one third of the patients on BCG regimen relapse within the first year of treatment. This study aimed at identifying biomarkers to predict response to BCG treatment. Methods: Gene expression was analyzed in blood cells of 58 patients treated with BCG through six consecutive weekly instillations and then at month 3, 6, 9, and 12. Cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-10, interferon (IFN)-γ, IL-1β, IL-2, IL-4, and IL-6; chemokines CCL2, CCL3,... Read more
    J Cancer Metastasis Treat 2017;3:116-26. | doi:10.20517/2394-4722.2017.25
    Published on: 14 Jul 2017  | Viewed:970  | Downloaded:42
    +HTML| PDF
  • Case Report|Open Access

    Alkaline phosphatase flare with hyperostosis of bone metastases in lung adenocarcinoma treated with gefitinib

    Hiroto Kaneko , Kazuho Shimura , Yosuke Matsumoto , Mihoko Yoshida , Masafumi Taniwaki , Junya Kuroda
    Alkaline phosphatase (ALP) flare has been reported to occur during cancer treatment as a favorable event, particularly in the presence of bone metastasis. There have been only a few reports in lung cancer and associated radiographic findings have seldom been described. The authors observed ALP flare in a female patient with lung adenocarcinoma soon after the initiation of gefitinib. Moreover, on computed tomography, metastatic lesions of the rib and thoracic spine showed marked hyperostosis, with sizes larger than the original bone structure, suggesting efficacy of gefitinib. The... Read more
    J Cancer Metastasis Treat 2017;3:34-7. | doi:10.20517/2394-4722.2016.70
    Published on: 23 Feb 2017  | Viewed:859  | Downloaded:68
    +HTML| PDF
  • Topic: Cancer Immunotherapy|Open Access

    Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead

    Stanley J. Oiseth , Mohamed S. Aziz
    The knowledge that the body possesses natural defenses to combat cancer existed long before the modern period, with multiple anecdotal reports of tumors miraculously disappearing, sometimes spontaneously or after a febrile or infectious episode. Spontaneous tumor regression of untreated malignant tumors is currently a well-accepted albeit rare phenomenon, and it is recognized that immunosuppression is associated with a higher cancer risk. The treatment of bladder carcinoma by intravesical administration of live attenuated Bacillus Calmette-Guérin bacteria was shown to be very effective in... Read more
    J Cancer Metastasis Treat 2017;3:250-61. | doi:10.20517/2394-4722.2017.41
    Published on: 31 Oct 2017  | Viewed:819  | Downloaded:723
    +HTML| PDF
  • Letter to Editor|Open Access

    Use of a dedicated day care unit in a modern radiation oncology facility -- a short audit

    Tejinder Kataria , Susovan Banerjee , Nimesh Dahima , Deepak Gupta , Trinanjan Basu , Shikha Goyal
    J Cancer Metastasis Treat 2017;3:21-2. | doi:10.20517/2394-4722.2016.73
    Published on: 23 Jan 2017  | Viewed:793  | Downloaded:65
    +HTML| PDF
Journal of Cancer Metastasis and Treatment Print ISSN: 2394-4722; Online ISSN: 2454-2857
Quick Links
  • OAE Publishing Inc. (OAE) is an online open-access publisher specializing in the publication of biomedical peer-reviewed journals...

  • Contact us
  • Leave feedback
Copyright © 2017 OAE Publishing Inc. All Rights Reserved.